Ignite Creation Date:
2024-05-06 @ 8:23 PM
Last Modification Date:
2024-10-26 @ 3:26 PM
Study NCT ID:
NCT06360406
Status:
RECRUITING
Last Update Posted:
2024-07-15
First Post:
2024-04-08
Brief Title:
Real-World Treatment Study of Koselugo Selumetinib
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Study Overview
Official Title:
Real-World Treatment Study of Koselugo Selumetinib
Status:
RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
As part of a post-approval commitment the Korean health authority requests a study to characterize safety and effectiveness in patients treated with Koselugo Selumetinib an oral selective inhibitor of MAPK kinase MEK 1 and 2 by physicians in routine clinical practice settings This study is designed to assess the known safety profile or identify previously unsuspected adverse reactions and evaluate the effectiveness of Koselugo under conditions of routine daily medical practice in Korea
This study will provide information on the Korean patient population that is treated with the study drug
This study will provide information on the Korean patient population that is treated with the study drug
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None